Susanne Arnold
11
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.4%
4 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Role: lead
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
Role: lead
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
Role: lead
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
Role: lead
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
Role: lead
Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning
Role: lead
Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Role: lead
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
Role: lead
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
Role: lead
A Protocol of Irinotecan for Carcinoma of the Lung
Role: lead
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
Role: lead
All 11 trials loaded